122 related articles for article (PubMed ID: 12165900)
21. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
Rasche M; Zimmermann M; Borschel L; Bourquin JP; Dworzak M; Klingebiel T; Lehrnbecher T; Creutzig U; Klusmann JH; Reinhardt D
Leukemia; 2018 Oct; 32(10):2167-2177. PubMed ID: 29550834
[TBL] [Abstract][Full Text] [Related]
22. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Litzow MR; Othus M; Cripe LD; Gore SD; Lazarus HM; Lee SJ; Bennett JM; Paietta EM; Dewald GW; Rowe JM; Tallman MS;
Br J Haematol; 2010 Jan; 148(2):217-25. PubMed ID: 19804455
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in management of acute myeloid leukemia (AML).
Shah M; Agarwal B
Indian J Pediatr; 2008 Aug; 75(8):831-7. PubMed ID: 18769895
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of liposomal daunorubicin in children.
Hempel G; Reinhardt D; Creutzig U; Boos J
Br J Clin Pharmacol; 2003 Oct; 56(4):370-7. PubMed ID: 12968981
[TBL] [Abstract][Full Text] [Related]
25. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
26. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
27. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
28. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
[TBL] [Abstract][Full Text] [Related]
30. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
31. [Low dose cytarabine in the treatment of acute myeloid leukemia. Apropos of 41 cases].
Frikha M; Elloumi M; Bouaziz M; Daoud J; Mseddi S; Khanfir A; Gargouri J; Souissi T
Bull Cancer; 1996 Dec; 83(12):996-1001. PubMed ID: 9116380
[TBL] [Abstract][Full Text] [Related]
32. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
Fassas A; Anagnostopoulos A
Leuk Lymphoma; 2005 Jun; 46(6):795-802. PubMed ID: 16019523
[TBL] [Abstract][Full Text] [Related]
33. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
Carella AM; Berman E; Maraone MP; Ganzina F
Haematologica; 1990; 75(2):159-69. PubMed ID: 2192943
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
